BTG2 Antibody

說明書

中文名稱：

BTG2兔多克隆抗體
貨號：

CSB-PA124546
規格：

￥1100
圖片：
Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane: Human liver cancer tissue, Primary antibody: CSB-PA124546(BTG2 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 minutes
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

Uniprot No.：

P78543
基因名：

BTG2
別名：

B cell translocation gene 2 antibody; BTG family member 2 antibody; Btg2 antibody; BTG2_HUMAN antibody; Nerve growth factor inducible anti proliferative antibody; NGF inducible anti proliferative protein PC3 antibody; NGF-inducible anti-proliferative protein PC3 antibody; PC3 antibody; Pheochromacytoma cell 3 antibody; Protein BTG2 antibody; TIS21 antibody
宿主：

Rabbit
反應種屬：

Human,Mouse,Rat
免疫原：

Fusion protein of Human BTG2
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
抗體亞型：

IgG
純化方式：

Antigen affinity purification
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
產品提供形式：

Liquid
應用范圍：

ELISA,WB

推薦稀釋比：

Application	Recommended Dilution
ELISA	1:1000-1:2000
WB	1:200-1:1000

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Anti-proliferative protein; the function is mediated by association with deadenylase subunits of the CCR4-NOT complex. Activates mRNA deadenylation in a CNOT6 and CNOT7-dependent manner. In vitro can inhibit deadenylase activity of CNOT7 and CNOT8. Involved in cell cycle regulation. Could be involved in the growth arrest and differentiation of the neuronal precursors. Modulates transcription regulation mediated by ESR1. Involved in mitochondrial depolarization and neurite outgrowth.
基因功能參考文獻：
1. oncogenic miR-25-3p directly targets BTG2 in TNBC. Further studies revealed that the biological effects of miR-25-3p on TNBC cell proliferation and apoptosis were mediated through regulation of BTG2 and subsequent activation of AKT and ERK-MAPK signaling pathway. PMID: 29310680
2. Open data and immunohistochemical analysis were performed to confirm the role of TIS21(/BTG2) expression in various human breast cancer tissues. It was observed that TIS21(/BTG2) inhibited mTORc1 activity by reducing Raptor-mTOR interaction along with upregulation of tsc1 expression. PMID: 29808317
3. we found that miR-27-3p was overexpressed in gastric cancer tissues and cell lines and that BTG2 was a direct and functional target of miR-27a-3p in gastric cancer PMID: 27409164
4. decreases tumorigenesis of hepatocellular carcinoma cell line side population cells PMID: 29098552
5. Effect of TIS21 on the regulation of p53 activity was confirmed by knockdown of TIS21 expression by RNA interference. PMID: 27208501
6. Data indicate that BTG2, MAP3K11, RPS6KA1 and PRDM1 as putative targets of microRNA miR-125b. PMID: 27613090
7. The results indicated that BTG2 expression was downregulated in skin cancer cell lines. Overexpression of BTG2 significantly inhibited cell proliferation, cell cycle progression, and the invasion and migration of skin cancer cells. PMID: 27510158
8. Overexpression of BTG2 inhibited the proliferation and migration/invasion of human osteosarcoma cells in vitro PMID: 26722427
9. clinical data support conclusions generated from patient-derived xenograft models and indicate that BTG2 expression is a candidate prognostic biomarker for TNBC. PMID: 26818199
10. miR-21 was found to be overexpressed and BTG2 was found to to be downregulated in HepG2 liver cancer cells. PMID: 26151427
11. BTG2 stimulates mRNA deadenylation via CAF1 activation through interaction with PABPC1. Interaction of BTG2 with the first RRM domain of PABPC1 is required for BTG2 to control cell proliferation. PMID: 26912148
12. SETD1A suppresses BTG2 expression through its induction of several BTG2-targeting miRNAs. PMID: 26394836
13. Results indicate that miR27a and BTG2 promote the migration and the growth of glioblastoma (GBM) cells and miR27a directly targets BTG2 in GBM cells. PMID: 25626081
14. Our results indicated that cisplatin attenuates prostate cancer cell proliferation partly mediated by upregulation of BTG2 through the p53-dependent pathway or p53-independent NFkappaB pathway. PMID: 24981574
15. In this review, we summarize the latest findings in BTG2 studies, highlighting the mechanisms for the regulatory effects of microRNAs (miRNAs) on BTG2 gene expression in the most common human cancers. PMID: 25405282
16. By applying loss-and-gain function analysis in NSCLC cell lines, we demonstrated that miR-25-BTG2 axis could directly regulated BTG2 expression and affect radiotherapy sensitivity of NSCLC cells. PMID: 25576360
17. An association with Graves disease was shown for several SNPs in BTG2. PMID: 24780075
18. BTG2 expression was inversely correlated with increased expression of the DNA methyltransferases DNMT1 and DNMT3a in MIBC, but not NMIBC, suggesting a potential role for BTG2 expression in muscle invasion of bladder cancer PMID: 25284287
19. Reactive oxygen spieces regulate Btg2/TIS21/PC3 expression via Protein kinase C-NFkappaappaB pathway. PMID: 23876794
20. TIS21 decreased interleukin-6 (IL-6) expression in human dermal fibroblast. PMID: 23917204
21. miR-21 is involved in MNNG-induced gastric carcinogenesis in vivo and in vitro via FASLG/BTG2 pathway. PMID: 24821435
22. BTG2 is a significant factor in tamoxifen response, acting through modification of AKT activation in ER-positive/HER2-negative breast cancer. PMID: 24698107
23. pro-apoptotic pathway of CRP-CD32-Nox2-p53-BTG2 may contribute to the retardation of the atherogenic process PMID: 24440351
24. Data indicate that the pattern of B cell translocation gene 2 (BTG2) protein expression was exactly the opposite of miRNA-21 expression in lung cancer cells. PMID: 23857284
25. BTG2 mediates crosstalk between PI3K-Akt1 and NF-kappaB pathways, which regulates p53-independent induction of G2/M phase arrest both in normal and cancer cells. PMID: 24047462
26. BTG2 can improve the radiosensitivity of breast cancer cells by affecting cell cycle distribution, enhancing radiation-induced apoptosis, and inhibiting DNA repair-related protein expression. PMID: 24308156
27. TIS21 suppresses invadopodia formation as well as invasion activity along with F-actin remodeling. PMID: 23907596
28. Downregulation of the basal protein B-cell translocation gene 2 is associated with prostate cancer transformation and progression. PMID: 22614007
29. These results indicate that endogenous BTG2 expression contributes to the migratory potential of bladder cancer cells. Moreover, high levels of BTG2 in bladder cancers are linked to decreased cancer-specific survival. PMID: 23299537
30. TIS21 regulates DNA double strand break repair and apoptosis via increasing Mre11 methylation. PMID: 23089312
31. study reveals that BTG2 negatively regulated cancer cell migration by inhibiting Src activity through downregulation of reactive oxygen species generation in mitochondria PMID: 22562501
32. MIR32 is upregulated in prostate cancer and regulates expression of BTG2. PMID: 22266859
33. a novel role for BTG2 as a co-activator for NFE2L2 in up-regulating cellular antioxidant defenses. PMID: 22493435
34. Results suggest that the overexpression of B cell translocation gene 2 (BTG2) may inhibit the growth, proliferation, and invasiveness of the A549 lung cancer cell line. PMID: 22392501
35. Estrogen receptor beta causes a G2 cell cycle arrest by inactivating CDK1 through the repression of cyclin B1 and stimulation of GADD45A and BTG2 expression. PMID: 21120602
36. These findings, for the first time, demonstrate that BTG2 complexes with AR via an LxxLL-dependent mechanism and may play a role in prostate cancer via modulating the AR signaling pathway. PMID: 21172304
37. The neutralization of Pin1 by BTG2 provides a critical mechanism to maintain senescent arrest in the presence of mitogenic signals in normal primary fibroblasts. PMID: 20569234
38. The influence of BTG2 on the growth, proliferation, apoptosis, invasion and cell cycle of the gastric cancer cell lines, was investigated. PMID: 19728149
39. High-level BTG2 protein expression correlates with prolonged survival in patients with breast carcinoma. PMID: 20553615
40. miR-18 may negatively regulate the expression of BTG2 in HepG2 cells. PMID: 19203451
41. Transient expression assays with BTG2/TIS21/PC3 promoter deletions and electrophoretic mobility shift analysis identified a major wild-type p53 response element located -74 to -122 relative to the start codon. PMID: 11814693
42. Antiproliferative proteins of the BTG/Tob family are degraded by the ubiquitin-proteasome system. the C-terminal regions are necessary and sufficient to control the stabilities of BTG1, BTG2, Tob, and Tob2 proteins. PMID: 12135500
43. BTG2 interacts with the CCR4 complex and has a role in cell-cycle regulation PMID: 12771185
44. deregulation of BTG2 may be an important step in the development of mammary tumors PMID: 15378000
45. DeltaNp73alpha not only acts as an inhibitor of p53/TAp73 functions in neuroblastoma tumors, but also cooperates with wt-p53 in playing a physiological role through the activation of BTG2TIS21/PC3 gene expression PMID: 15741235
46. binding of tis21/BTG2/pc3 to Pin-1 or cyclin B1-Cdc2 complex and induction of mitochondrial depolarization are responsible for the antiproliferative effects of EGF in human tumor cells PMID: 15788397
47. BTG2 expression was found to be significantly reduced in a large proportion of human kidney and breast carcinomas, suggesting that BTG2 is a tumor suppressor that links p53 and Rb pathways in human tumorigenesis. PMID: 16418486
48. BTG2 contributes to retinoic acid activity by favoring differentiation through a gene-specific modification of histone H4 arginine methylation and acetylation levels. PMID: 16782888
49. Reverse-transcription polymerase chain reaction confirmed increased expression of GADD45A, BTG2, PDE4B, and CEBPD and downregulation of TOB1 in skeletal muscle intradialysis. PMID: 16997058
50. T3 upregulates proliferation of LNCaP cells by downregulating BTG2 gene expression through the consensus TRE pathway. PMID: 18196550
顯示更多

收起更多
蛋白家族：

BTG family
數據庫鏈接：

HGNC: 1131

OMIM: 601597

KEGG: hsa:7832

STRING: 9606.ENSP00000290551

UniGene: Hs.519162

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
VIM Recombinant Monoclonal Antibody

Applications: ELISA, IHC, IF

Species Reactivity: Human